“The integrated analysis across the machine, map, mood, and mechanics pillars supports a moderate risk posture for CAR-T cell therapy in solid tumors. All pillars align on the core narrative: substantial biological and logistical barriers persist, but parallel advances in decentralized manufacturing, engineering payloads, and tumor microenvironment modulation create a credible path to incremental success. The absence of significant divergences indicates a cohesive understanding of the challenges and opportunities, reinforcing confidence that focused investment in next-generation CAR designs and streamlined production can gradually lower the overall risk profile over the next 3–5 years.”